bpc 157 clinical trial registry bpc-157 tb-500 protocol bpc-157 Amazon.com: The Peptide Therapy Protocols Bible: Ultimate Guide to BPC-157 FDA Approval Status 2026:
Description
(2024, submitted)
Store per the label
Subcutaneous planning from a 50 mg vial reconstituted with 3.0 mL BAC water (~16.7 mg/mL) Phase Days 12 (tolerance) Daily dose 2.5 mg once daily Units on U-100 syringe 15 units Volume 0.15 mL Phase Days 3+ (standard) Daily dose 5 mg once daily Units on U-100 syringe 30 units Volume 0.30 mL Phase Split option (BID) Daily dose 2.5 mg twice daily Units on U-100 syringe 15 units each Volume 0.15 mL each Subcutaneous doses are much smaller than oral doses because of injection volume limits and because direct subQ absorption skips the gut
The first and only state
